文献速递药物相互作用特殊人群用药

皮质类固醇与霉酚酸药代动力学相互作用的临床证据

Clinical Evidence on the Purported Pharmacokinetic Interactions between Corticosteroids and Mycophenolic Acid.
PubMed 文献 · Clin Pharmacokinet · 2023-02-27

本文旨在批判性评估皮质类固醇与霉酚酸(MPA)药代动力学相互作用的临床数据,并提出了基于MPA药理学的新的评估标准。检索PubMed和Embase数据库至2022年9月29日,共纳入8篇支持相互作用的论文和22篇不支持相互作用的论文。总体评估表明,当前临床文献中尚无支持该相互作用的决定性机制数据,需要进一步研究量化类固醇减量或撤药对MPA药代动力学的影响。

要点

  • 现有临床证据不足以证实皮质类固醇与MPA存在药代动力学相互作用
  • 多数数据涉及泼尼松或泼尼松龙,缺乏决定性机制数据
  • 需进一步研究类固醇减量或撤药对MPA药代动力学的影响

核心结论

  • 当前临床文献中无支持皮质类固醇与MPA药代动力学相互作用的决定性机制数据。

研究设计与样本

  • 本文为Current Opinion,检索PubMed和Embase数据库至2022年9月29日的英文临床文章,共识别8篇支持相互作用的论文和22篇不支持的论文。

主要发现

  • 共识别8篇支持相互作用的论文和22篇不支持相互作用的论文,多数数据涉及泼尼松或泼尼松龙。

关键数值与推荐

  • 提出了基于已知MPA药理学的新的评估标准,包括独立对照组、泼尼松龙浓度、MPA代谢物数据、游离MPA浓度、肠肝循环和MPA肾清除率的表征。

临床怎么用

  • 临床应认识到当前证据不足以证实该相互作用,需进一步研究类固醇减量或撤药对MPA药代动力学的影响。

局限性

  • 当前临床文献缺乏决定性机制数据,需进一步转化研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Corticosteroids (steroids) are commonly used concurrently with mycophenolic acid (MPA) as the first-line immunosuppression therapy for the prevention of rejection in solid organ transplantations. Steroids are also commonly administered with MPA in various autoimmune disorders such as systemic lupus erythematosus and idiopathic nephrotic syndrome. Despite various review articles having suggested the presence of pharmacokinetic interactions between MPA and steroids, definitive data have not yet been demonstrated. The aim of this Current Opinion is to critically evaluate the available clinical data and propose the optimal study design for characterising the MPA-steroid pharmacokinetic interactions. The PubMed and Embase databases were searched for relevant clinical articles in English as of September 29, 2022, where a total of 8 papers have been identified as supporting and 22 as non-supporting the purported drug interaction. To objectively evaluate the data, novel assessment criteria to effectively diagnose the interaction based on known MPA pharmacology were formulated, including the availability of independent control groups, prednisolone concentrations, MPA metabolite data, unbound MPA concentrations, and the characterisations of entero-hepatic recirculation and MPA renal clearance. Overall, the majority of the identified corticosteroid data were pertaining to prednisone or prednisolone. Our assessment indicated that no conclusive mechanistic data supporting the interaction are available in the current clinical literature, and further studies are required to quantify the effects/mechanisms of steroid-tapering or withdrawal on MPA pharmacokinetics. This current opinion provides justification for further translational investigations, as this particular drug interaction has the potential to exert significant adverse outcomes in patients prescribed MPA.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Rong Y, Kiang T. Clinical Evidence on the Purported Pharmacokinetic Interactions between Corticosteroids and Mycophenolic Acid. Clin Pharmacokinet. 2023. PMID: 36848031. doi:10.1007/s40262-023-01212-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。